Shares of Hims & Hers Health plunged Friday after the Food & Drug Administration said a shortage of the active ingredient in ...

Regeneron (NASDAQ: REGN) is testing its drug, trevogrumab, along with Wegovy and another treatment, garetosmab, in a ...

We will continue to offer access to personalized treatments as allowed by law to meet patient needs,” Hims & Hers CEO said.

David Ricks said drugs like Mounjaro and Zepbound are priced to reflect the costs involved, patent expiry, and the enormous ...

Federal regulators say shortages of Ozempic and Wegovy have been resolved, as supplies of popular diabetes and obesity ...

President Donald Trump and HHS Secretary Robert F. Kennedy Jr. said they will be studying the "threat" to children posed by ...

More than 15.5 million Americans have tried weight loss injectables, but risks are rising with the proliferation of ...

(Reuters) - Current weight-loss methods such as lifestyle changes, surgery, and popular therapies like Novo Nordisk (NYSE:NVO)'s Wegovy and Eli Lilly (NYSE:LLY)'s Zepbound result in both fat and ...

Two Omaha women lost more than 300 lbs. combined with injections of a GLP-1 drug, which are used increasingly for weight loss ...

The latest weight-loss drugs including Ozempic, Wegovy, Mounjaro ... America's 10th-largest company that's worth nearly $830 billion. The stock has risen 17% in the past year, and more than ...

The telehealth company has been selling a copycat version of a popular obesity drug during the recent shortage.

Eli Lilly Chief Scientific Officer Dan Skovronsky spoke to CNBC about obesity pills and more on the future of weight loss.